Skip to main content
SpringerLink
Log in

Managing Antipsychotic-Induced Parkinsonism

  • Practical Drug Safety
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Notwithstanding the advent of clozapine and other ‘atypical’ antipsychotic agents, the conventional (‘typical’) antipsychotic agents remain in widespread use. Antipsychotic-induced parkinsonism is a highly prevalent adverse effect that may result in increased morbidity and noncompliance.

Bedside examination is generally sufficient for the detection of the onset of parkinsonism and should be carried out frequently in the first 3 months of treatment. In addition to decreasing patient discomfort, monitoring for antipsychotic-induced parkinsonism also serves to identify the minimally effective dosage required for the individual patient.

Several strategies are utilised in the management of antipsychotic-induced parkinsonism including dosage reduction, switching to other antipsychotic agents and the use of antiparkinsonian drugs such as anticholinergic agents and amantadine.

Anticholinergic agents remain the mainstay of the pharmacological management of antipsychotic-induced parkinsonism in younger patients. Amantadine is a better tolerated agent for elderly patients, with similar efficacy to the anticholinergic agents. The routine use of prophylactic anticholinergics is not recommended and is clearly contraindicated in the elderly. An individualised risk-benefit assessment is necessary for the younger patient in whom prophylactic use of anticholinergic drugs is considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Ach Gen Psychiatry 1988; 45 789–96

    Article  CAS  Google Scholar 

  2. Gerlach J. New antipsychotics: classification, efficacy and adverse effects. Schizophr Bull 1991; 17: 289–309

    Article  PubMed  CAS  Google Scholar 

  3. Tandon R. Neuropharmacologic basis for clozapine’s unique profile [letter]. Arch Gen Psychiatry 1993; 50: 158–9

    Article  PubMed  CAS  Google Scholar 

  4. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549–57

    Article  PubMed  CAS  Google Scholar 

  5. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 1995; 120: 128–33

    Article  CAS  Google Scholar 

  6. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35

    PubMed  CAS  Google Scholar 

  7. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-center, doubleblind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712–26

    Article  PubMed  CAS  Google Scholar 

  8. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125–37

    Article  PubMed  CAS  Google Scholar 

  9. Wilson JA, Maclennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989; 18: 208–10

    Article  PubMed  CAS  Google Scholar 

  10. Casey DE. Side effect profiles of new antipsychotics. J Clin Psychiatry 1996; 57 (S11): 40–5

    PubMed  CAS  Google Scholar 

  11. Sweet RA, Mulsant BH, Pollock BG, et al. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer’s type. Am J Geriatr Psychiatry 1996; 4: 311–9

    Google Scholar 

  12. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175(12): 1054–60

    Article  PubMed  CAS  Google Scholar 

  13. Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85–9

    PubMed  CAS  Google Scholar 

  14. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974; 31: 58–61

    Article  PubMed  CAS  Google Scholar 

  15. Meltzer H Y, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical anti-psychotic drugs. Psychopharmacol Bull 1989; 25: 390–2

    PubMed  CAS  Google Scholar 

  16. Villeneuve JL. The rabbit syndrome: a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 1972; 17: 69–72

    Google Scholar 

  17. Sweet RA, Pollock BG, Rosen J, et al. Early detection of neuroleptic-induced parkinsonism in the elderly patients with dementia. J Geriatr Psychiatry Neurol 1994; 7: 251–4

    PubMed  CAS  Google Scholar 

  18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 21: 211–8

    Google Scholar 

  19. Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci 1993; 5: 56–60

    PubMed  CAS  Google Scholar 

  20. Caliguri M P. Portable device for quantifying parkinsonism wrist rigidity. Mov Disord 1994; 9: 57–63

    Article  Google Scholar 

  21. Shriqui CL. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can J Psychiatry 1995; 40 (2 Suppl.): 38S–48S

    Google Scholar 

  22. Haase HJ. Extrapyramidal modifications of fine movements: a ‘conditio sine qua non’ of the fundamental therapeutic action of neuroleptic drugs. In: Bordeleau JM, editor. Systeme extrapyramidal et neuroleptiques. Montreal: Editions Psychiatriques 1961: 329–53

    Google Scholar 

  23. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991; 48: 739–45

    Article  PubMed  CAS  Google Scholar 

  24. Haase HJ. Clinical observations on the actions of neuroleptics. In: Haase HJ, Janssen PA, editors. The actions of neuroleptic drugs: a psychiatric, neurological, and pharmacological investigation. Amsterdam: N Holland, 1965: 1–98

    Google Scholar 

  25. Haase HJ, Janssen PAJ, editors. The actions of neuroleptic drugs. New York: Elsevier, 1985

    Google Scholar 

  26. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harvard Rev Psychiatry 1995; 2: 327–35

    Article  CAS  Google Scholar 

  27. Ayd FJ. Early onset neuroleptic-induced extrapyramidal reactions: a second survey, 1961–1981. In: Coyle JT, Enna SJ, editors. Neuroleptics: neurochemical, behavioural, and clinical perspectives. New York: Raven Press, 1983: 75–92

    Google Scholar 

  28. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harv Rev Psychiatry 1995; 2(6): 327–35

    Article  PubMed  CAS  Google Scholar 

  29. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 1994; 2: 204–13

    Article  PubMed  CAS  Google Scholar 

  30. Palmer AM, DeKosky ST. Monamine neurons in aging and Alzheimer’s disease. J Neural Trans 1993; 91: 135–59

    Article  CAS  Google Scholar 

  31. Branchey MH, Branchey LB, Richardson MAR. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 1981; 138: 608–12

    PubMed  CAS  Google Scholar 

  32. Ayd FJ. Neuroleptics and antiparkinsonian drugs. Int Drug Ther Newsl 1971; 6: 33–6

    Google Scholar 

  33. Shapiro AK. Psychochemotherapy. In: Grenell RO, Gabay S, editors. Biological foundations of psychiatry. New York: Raven Press, 1971: 793–840

    Google Scholar 

  34. Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsych Biol Psychiatry 1997; 21: 1059–94

    Article  CAS  Google Scholar 

  35. Kalish SC, Bohn R, Mogun B, et al. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Am Geriatr Soc 1995; 43(9): 967–73

    PubMed  CAS  Google Scholar 

  36. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22(1): 254–9

    PubMed  CAS  Google Scholar 

  37. Singh M. Therapeutic reversal with benztropine in schizophrenia. J Nerv Ment Dis 1975; 160: 258–66

    Article  PubMed  CAS  Google Scholar 

  38. Johnston EC, Crow TJ, Ferrier IN, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513–27

    Article  Google Scholar 

  39. DiMascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599–60

    Article  PubMed  CAS  Google Scholar 

  40. Aoki F, Sitar D. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35–51

    Article  PubMed  CAS  Google Scholar 

  41. Gianutsos G, Stewart C, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985; 110: 357–61

    Article  PubMed  CAS  Google Scholar 

  42. Hamlin T. Current concepts in therapy: agents for treatment of Parkinson’s disease. N Engl J Med 1975; 256: 699–701

    Google Scholar 

  43. Yadalam KG. Drug-inducedparkinsonism. In: Keshavan MS, Kennedy JS, editors. Drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation, 1992: 119–29

    Google Scholar 

  44. Yaryura-Tobias JA, Wolpert A, Dana L, et al. Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst 1970; 31: 60–3

    PubMed  CAS  Google Scholar 

  45. Rajput A, Rozdilsky B, Hornykiewicz O, et al. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982; 39: 644–6

    Article  PubMed  CAS  Google Scholar 

  46. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 1994; 14(5): 543–60

    PubMed  CAS  Google Scholar 

  47. Winslow RS, Stillner V, Coons DJ, et al. Prevention of acute dystonic reactions in patients beginning high potency neuroleptics. Am J Psychiatry 1986; 143: 706–10

    PubMed  CAS  Google Scholar 

  48. World Health Organization, Heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990; 156: 412

    Article  Google Scholar 

  49. Barnes TRE. Comment on WHO consensus statement. Br J Psychiatry 1990; 156: 413–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, 3811 O’Hara Street, Pittsburgh, Philadelphia, 15213-2593, USA

    David C. Mamo, Robert A. Sweet & Matcheri S. Keshavan

Authors
  1. David C. Mamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Sweet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matcheri S. Keshavan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Mamo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mamo, D.C., Sweet, R.A. & Keshavan, M.S. Managing Antipsychotic-Induced Parkinsonism. Drug-Safety 20, 269–275 (1999). https://doi.org/10.2165/00002018-199920030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920030-00006

Keywords

Search

Navigation